Drug Trial Radar · NCT05142774
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
728
Actual
Start
Oct 28, 2021
Primary completion
Feb 29, 2024
Study completion Mar 7, 2024
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
Conditions
- Atopic Dermatitis
Interventions
Tapinarof cream, 1%Drug
Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse EventsTime frame: Baseline to Week 49
- Frequency of Adverse Events and Serious Adverse EventsTime frame: Baseline to Week 49
- Change From Baseline in Clinical Laboratory Values (g/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (U/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (mmol/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (Umol/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (10^9 Cells/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (%)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (L/L)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (pg)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (fl)Time frame: Baseline to Week 48
- Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)Time frame: Baseline to Week 48
- Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )Time frame: Baseline to Week 48
- Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)Time frame: Baseline to Week 48
- Absolute Change From Baseline in %BSA AffectedTime frame: Baseline to Week 48
- Percent Change From Baseline in %BSA AffectedTime frame: Baseline to Week 48
- Mean Change From Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline to Week 48
- Percent Change From Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline to Week 48
- Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
- Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
- Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
- Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From BaselineTime frame: Baseline to Week 48
- Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From BaselineTime frame: Baseline to Week 48
- Change From Baseline in Vital Signs - PulseTime frame: Baseline to Week 48
- Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)Time frame: Baseline to Week 48
- Change From Baseline in Vital Signs - TemperatureTime frame: Baseline to Week 48
Locations
112 sites in 2 countries. Site status is shown where the registry gives one.
Dermavant Investigative Site
Birmingham, Alabama
Dermavant Investigative Site
Phoenix, Arizona
Dermavant Investigative Site
Scottsdale, Arizona
Dermavant Investigative Site
Scottsdale, Arizona
Dermavant Investigative Site
Bryant, Arkansas
Dermavant Investigative Site
Fort Smith, Arkansas
Dermavant Investigative Site
Cerritos, California
Dermavant Investigative Site
Fountain Valley, California
Dermavant Investigative Site
Fremont, California
Dermavant Investigative Site
Huntington Beach, California
Dermavant Investigative Site
Inglewood, California
Dermavant Investigative Site
Lancaster, California
Dermavant Investigative Site
Long Beach, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Los Angeles, California
Dermavant Investigative Site
Mission Viejo, California
Dermavant Investigative Site
Sacramento, California
Dermavant Investigative Site
San Diego, California
Dermavant Investigative Site
San Francisco, California
Dermavant Investigative Site
Santa Ana, California
Dermavant Investigative Site
Santa Monica, California
Dermavant Investigative Site
Thousand Oaks, California
Dermavant Investigative Site
Thornton, Colorado
Dermavant Investigative Site
Washington D.C., District of Columbia
Dermavant Investigative Site
Boca Raton, Florida
Dermavant Investigative Site
Boca Raton, Florida
Dermavant Investigative Site
Brandon, Florida
Dermavant Investigative Site
Coral Gables, Florida
Dermavant Investigative Site
Delray Beach, Florida
Dermavant Investigative Site
Hialeah, Florida
Dermavant Investigative Site
Jacksonville, Florida
Dermavant Investigative Site
Margate, Florida
Dermavant Investigative Site
Miami, Florida
Dermavant Investigative Site
Miami, Florida
Dermavant Investigative Site
Miami Lakes, Florida
Dermavant Investigative Site
Orlando, Florida
Dermavant Investigative Site
Pinellas Park, Florida
Dermavant Investigative Site
Sweetwater, Florida
Dermavant Investigative Site
Tampa, Florida
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.